عرض بسيط للتسجيلة

المؤلفRoberts, Matthew J.
المؤلفYaxley, John W.
المؤلفCoughlin, Geoffrey D.
المؤلفGianduzzo, Troy R.J.
المؤلفEsler, Rachel C.
المؤلفDunglison, Nigel T.
المؤلفChambers, Suzanne K.
المؤلفMedcraft, Robyn J.
المؤلفChow, Clement W.K.
المؤلفSchirra, Horst Joachim
المؤلفRichards, Renee S.
المؤلفKienzle, Nicholas
المؤلفLu, Macy
المؤلفBrereton, Ian
المؤلفSamaratunga, Hema
المؤلفPerry-Keene, Joanna
المؤلفPayton, Diane
المؤلفOyama, Chikara
المؤلفDoi, Suhail A.
المؤلفLavin, Martin F.
المؤلفGardiner, Robert A.
تاريخ الإتاحة2017-06-12T08:47:53Z
تاريخ النشر2016-09
اسم المنشورContemporary Clinical Trialsen_US
المعرّفhttp://dx.doi.org/10.1016/j.cct.2016.06.014
الاقتباسMatthew J. Roberts, John W. Yaxley, Geoffrey D. Coughlin, Troy R.J. Gianduzzo et al. "Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol, Contemporary Clinical Trials", Volume 50, 2016, Pages 16-20, ISSN 1551-7144
الرقم المعياري الدولي للكتاب15517144
معرّف المصادر الموحدhttp://www.sciencedirect.com/science/article/pii/S1551714416300969
معرّف المصادر الموحدhttp://hdl.handle.net/10576/5567
الملخصBackground Atorvastatin and metformin are known energy restricting mimetic agents that act synergistically to produce molecular and metabolic changes in advanced prostate cancer (PCa). This trial seeks to determine whether these drugs favourably alter selected parameters in men with clinically-localized, aggressive PCa. Methods/design This prospective phase II randomized, controlled window trial is recruiting men with clinically significant PCa, confirmed by biopsy following multiparametric MRI and intending to undergo radical prostatectomy. Ethical approval was granted by the Royal Brisbane and Women's Hospital Human and The University of Queensland Medical Research Ethics Committees.Participants are being randomized into four groups: metformin with placebo; atorvastatin with placebo; metformin with atorvastatin; or placebo alone. Capsules are consumed for 8weeks, a duration selected as the most appropriate period in which histological and biochemical changes may be observed while allowing prompt treatment with curative intent of clinically significant PCa. At recruitment and prior to RP, participants provide blood, urine and seminal fluid. A subset of participants will undergo 7Tesla magnetic resonance spectroscopy to compare metabolites in-vivo with those in seminal fluid and biopsied tissue.The primary end point is biochemical evolution, defined using biomarkers (serum prostate specific antigen; PCA3 and citrate in seminal fluid and prostatic tissue). Standard pathological assessment will be undertaken. Discussion This study is designed to assess the potential synergistic action of metformin and atorvastatin on PCa tumour biology. The results may determine simple methods of tumour modulation to reduce disease progression.
اللغةen
الناشرElsevier
الموضوعProstate cancer
الموضوعAtorvastatin
الموضوعMetformin
الموضوعClinical trial
الموضوعBiomarkers
الموضوعMetabolomics
العنوانCan atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol
النوعArticle
الصفحات16-20
رقم المجلد50
elsevier.identifier.scopusid 84978698686


الملفات في هذه التسجيلة

الملفاتالحجمالصيغةالعرض

لا توجد ملفات لها صلة بهذه التسجيلة.

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة